MIT

GSK further extends HGS tender offer

Friday, June 29, 2012 02:14 PM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on July 20, 2012.

More... »

GSK receives FDA approval for MenHibrix

Monday, June 18, 2012 12:33 PM

The FDA has approved GlaxoSmithKline’s vaccine MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b in children aged six weeks through 18 months.

More... »

HGS sets July 16 deadline for acquisition proposals

Friday, June 15, 2012 02:09 PM

In connection with its ongoing strategic alternative review process, Human Genome Sciences (HGS) has set a bid date of July 16, 2012, for the submission of definitive proposals to acquire all outstanding common shares of HGS.

More... »

Upsher-Smith to acquire U.K.-based Proximagen

Thursday, June 14, 2012 12:33 PM

Upsher-Smith Laboratories, a privately-owned specialty pharmaceutical company of Maple Grove, Minn., has agreed to acquire Proximagen Group, a European biotech focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. Upsher-Smith intends to retain operations in Cambridge and London, England.

More... »

GSK extends tender offer for HGS shares

Monday, June 11, 2012 09:49 AM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on Friday, June 29, 2012. The tender offer was previously scheduled to expire at 12:00 midnight EST, at the end of the day on June 7, 2012.

More... »

GSK’s Hart-Scott-Rodino waiting period expires for HGS tender offer

Monday, June 4, 2012 10:55 AM

GlaxoSmithKline’s waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, expired as of June 1, 2012, giving GSK clearance to acquire all outstanding shares of Human Genome Sciences.

More... »

Two GSK melanoma drugs garner top results

Monday, June 4, 2012 10:21 AM

GlaxoSmithKline released results from two of its phase III melanoma studies: one evaluating single agent therapy with the targeted anti-cancer agents, dabrafenib and trametinib, in patients with BRAF V600 mutation positive metastatic melanoma; and one evaluating trametinib alone.

More... »

CDRD, CDRD Ventures, GSK collaborate to advance Canadian health research

Friday, June 1, 2012 03:07 PM

The Centre for Drug Research and Development (CDRD), its commercial arm, CDRD Ventures (CVI), and global pharmaceutical company GlaxoSmithKline (GSK) in have entered into a strategic collaboration that will provide new financial resources as well as leading drug development expertise to be applied to the development and commercialization of health research conducted in Canadian research institutions.

More... »

Stiefel to acquire psoriasis topical agent from Welichem Biotech

Thursday, May 31, 2012 02:24 PM

Stiefel, a subsidiary of GlaxoSmithKline, has signed an agreement with Canada-based Welichem Biotech to acquire exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.

More... »

GSK and HKCF establish Cancer Drug Relief Fund in Hong Kong

Wednesday, May 30, 2012 02:48 PM

In a joint effort, GlaxoSmithKline and Hong Kong Cancer Fund have established the Cancer Drug Relief Fund, a $5.4 million three-year pilot project dedicated to offering financial assistance by way of subsidized cancer drugs to low income patients and those in the “sandwich class.”

More... »